MabCure Launches Clinical Trial to Diagnose Ovarian Cancer
News Jan 07, 2010
MabCure, N.V. (MabCure) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.
The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.
“MabCure’s proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well.”
Dr. Amnon Gonenne, MabCure’s President and CEO commented, “We are very excited about the commencement of this study. We have been working hard to establish key partnerships with respectable research institutions and hospitals in Europe and the Far East, and this is no exception. We are looking forward to the results of the study and to moving MabCure forward towards having our diagnostic products on the market.”
“We know our diagnostic products have the potential to save many lives, and our mission is to get them to market as quickly as possible,” Dr. Gonenne added.
“MabCure’s proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well,” said Dr. Gonenne.
Lipid droplets have been found to play critical roles in the life cycles of certain proteins involved in gene expression. Now, a new study describes how lipid droplets regulate these proteins. The research has implications for understanding what helps embryos survive and could cause us to reconsider how we look at lipid-related diseases like obesity.READ MORE